French Three-City Study
Initiatives
-
The principal objective of the 3C-Study is to estimate the risk of dementia (Alzheimer’s disease and other types) that may be attributed to vascular factors. To reach this general objective, the following specific objectives must be attained:
1. To assess the associations of vascular diseases (CHD and stroke) with dementia and cognitive impairment;
2. To quantify the associations between cerebral white matter hyperintensities and dementia;
3. To quantify the associations of dementia with factors that increase or decrease the risk of vascular diseases;
4. To quantify the associations of cerebral measures (white matter hyperintensities and atrophy) with factors that increase or decrease the risk of vascular diseases.
- Start Year
- 1991
- End Year
- 2012
- Funding
- The Fondation pour la Recherche Médicale funded the preparation and initiation ofthe study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé,Conseils Régionaux of Aquitaine, Languedoc-Roussillon and Bourgogne, Fondation de France, Ministry of Research-INSERM Programme ‘Cohortes et collections de données biologiques’, Mutuelle Générale de l’Education Nationale, Institut de la longévité, Conseil Général de la Côte d’or.
Visit 3C Study
| Investigators | Contacts |
|---|---|
|
Design
- Study design
- Population cohort
- Follow Up
- Participants have been re-examined, on the average, every two years. Each follow-up examination includes a labour-intensive ascertainment of the main outcomes of the study. Dementia, coronary heart disease (CHD) and stroke cases are validated by panels of independent experts.
Marker Paper
3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology. 2003 Nov-Dec;22(6):316-25. doi: 10.1159/000072920.
PUBMED 14598854
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 9,294
- Number of participants with biosamples
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |